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OBJECTIVES The aim of the study was to evaluate whether adenosine infusion can induce production of
active renin and angiotensin II in human coronary circulation.
BACKGROUND Adenosine can activate angiotensin production in the forearm vessels of essential hypertensive
patients.
METHODS In six normotensive subjects and 12 essential hypertensive patients adenosine was infused into
the left anterior descending coronary artery (1, 10, 100 and 1,000 mg/min 3 5 min each)
while active renin (radioimmunometric assay) and angiotensin II (radioimmunoassay after
high performance liquid chromatography purification) were measured in venous (great cardiac
vein) and coronary arterial blood samples. In five out of 12 hypertensive patients adenosine
infusion and plasma samples were repeated during intracoronary angiotensin-converting
enzyme inhibitor benazeprilat (25 mg/min) administration. Finally, in adjunctive hypertensive
patients, the same procedure was applied during intracoronary sodium nitroprusside (n 5 4)
or acetylcholine (n 5 4).
RESULTS In hypertensive patients, but not in control subjects, despite a similar increment in coronary
blood flow, a significant (p , 0.05) transient increase of venous active renin (from 10.7 6 1.4
[95% confidence interval 9.4 to 11.8] to a maximum of 13.8 6 2.1 [12.2 to 15.5] with a
consequent drop to 10.9 6 1.8 [9.7 to 12.1] pg/ml), and angiotensin II (from 14.6 6 2.0
[12.7 to 16.5] to a maximum of 20.4 6 2.7 [18.7 to 22.2] with a consequent drop to 16.3 6
1.8 [13.9 to 18.7] pg/ml) was observed under adenosine infusion, whereas arterial values did
not change. Calculated venous–arterial active renin and angiotensin II release showed a strong
correlation (r 5 0.78 and r 5 0.71, respectively; p , 0.001) with circulating active renin. This
adenosine-induced venous angiotensin II increase was significantly blunted by benazeprilat.
Finally, both sodium nitroprusside and acetylcholine did not affect arterial and venous values
of active renin and angiotensin II.
CONCLUSIONS These data indicate that exogenous adenosine stimulates the release of active renin and
angiotensin II in the coronary arteries of essential hypertensive patients, and suggest that
this phenomenon is probably due to renin release from tissue stores of renally derived renin.
(J Am Coll Cardiol 1999;33:1677–84) © 1999 by the American College of Cardiology
Since the original description of the classical components of
the renin–angiotensin system (RAS) in the vessel wall,
considerable experimental evidence has suggested that the
RAS can act not only as a systemic, but also as a local
vascular system (1–5). More recently, the existence of a
vascular RAS has been proposed in human hypertension. It
has been demonstrated that beta-adrenergic receptor stim-
ulation causes the release of active and inactive renin and
angiotensin II in the forearm vessels of hypertensive patients
(6–10).
Adenosine is an endogenous substance that induces renin
release in in vitro models through the activation of its A2
receptors (11). This evidence has been confirmed in humans
by the finding that intrabrachial infusion of exogenous
adenosine causes the release of angiotensin II in the forearm
of essential hypertensive patients (12). Because adenosine is
synthesized in the myocardium, where it plays an important
role in the control of coronary circulation (13,14), the
present study was designed to evaluate whether exogenous
adenosine can stimulate a vascular RAS in human coronary
arteries. To investigate this issue, in normotensive subjects
and essential hypertensive patients, adenosine was infused
into the left anterior descending coronary artery (LAD);
simultaneously, sampling for determination of the values of
active renin and angiotensin II, the main components of the
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RAS cascade, was collected from the LAD and the great
cardiac vein to calculate the net balance, that is, release or
uptake, of these substances through the coronary circula-
tion.
METHODS
The study population included 6 normotensive control
subjects and 20 matched mild to moderate uncomplicated
essential hypertensive patients. Subjects with diabetes mel-
litus, hypercholesterolemia (total cholesterol greater than
5.2 mmol/liter), cerebral ischemic vascular disease, impaired
renal function or a smoking history of more than five
cigarettes per day were excluded from the study. Control
subjects were defined as normotensive according to the
absence of a familial history of essential hypertension and
blood pressure values below 140/90 mm Hg. All essential
hypertensive patients recruited reported the presence of a
positive family history of essential hypertension. Supine
arterial pressure (after 10 min of rest) measured by mercury
sphygmomanometer three times at one-week intervals was
consistently found to be greater than 140/90 mm Hg.
Secondary forms of hypertension were excluded from the
study by routine diagnostic procedures. In all patients the
absence of renovascular disease was previously evaluated by
a Doppler examination of the renal arteries and confirmed
by renal arteriography performed before coronary angiogra-
phy. When admitted to the ward patients were maintained
on a normocaloric diet with moderately low sodium (80 to
100 mmol/day) and normal potassium chloride (60 to 80
mmol/day) intake so that a constant sodium excretion rate
was obtained, usually on the fourth day of hospitalization.
On attainment of sodium equilibrium, peripheral venous
samples for active renin and angiotensin II were obtained
after patients had been standing for 1 h. Subjects were
selected among the hypertensive or normotensive patients
referred to the Department of Internal Medicine or the
Institute of Clinical Physiology for the presence of a chest
pain syndrome. Inclusion criteria were the positivity on a
provocative test such as effort electrocardiography or dipyr-
idamole echocardiography test and clinical conditions that
allowed the pharmacologic treatment to be withdrawn at
least one week before the study. Each subject subsequently
underwent coronary angiography that showed normal or
nonsignificant atherosclerotic lesions of epicardial coronary
arteries and normal left ventricular function. In accordance
with institutional guidelines, the protocol was approved by
the ethical committee of the University of Pisa. All patients
were aware of the investigational nature of the study and
gave written consent to it.
Experimental procedure. Diagnostic left heart catheter-
ization and coronary angiography were performed by a
standard percutaneous femoral approach, in the angio-
graphic laboratory of the Institute of Clinical Physiology of
Pisa. After completion of diagnostic catheterization,
10,000 U of heparin were given intravenously and a tem-
porary pacing wire was advanced in the right ventricle from
the femoral vein. A 7-F catheter was inserted in a left arm
vein and positioned in the great cardiac vein. An 8-F
guiding catheter was positioned in the left coronary ostium.
A 20-MHz pulsed Doppler crystal mounted on the tip of a
3-F infusion catheter (Millar Instruments, Houston, Texas)
was advanced through the guiding catheter into the proxi-
mal segment of the LAD. The Doppler catheter was
connected to a photographic multichannel oscillographic
recorder (Ote-Biomedica, Firenze, Italy) to display phasic
and mean velocity waveforms. Before beginning the exper-
imental protocol, the position of the Doppler flow velocity
catheter and the range gate control were adjusted to opti-
mize the audio flow velocity signal and the phasic flow
velocity waveform. The Doppler catheter position and range
gate control were not changed thereafter.
Experimental design. To evaluate the possibility that
adenosine could activate a vascular RAS in 12 essential
hypertensive patients and six normotensive subjects, aden-
osine was infused into the LAD at increasing cumulative
doses (1, 10, 100 and 1,000 mg/min 3 5 min each) in the
presence of intracoronary saline (0.4 ml/min), started
10 min earlier. Simultaneous arterial and venous samples for
active renin and angiotensin II were collected basally, at the
end of saline infusion and at the end of each adenosine dose.
To confirm the local origin of angiotensin II, in the final five
out of the 12 hypertensive patients adenosine was repeated
in the presence of benazeprilat, an angiotensin-converting
enzyme (ACE) inhibitor, infused into the LAD at the rate
of 25 mg/min, started 15 min before adenosine and contin-
ued throughout. Arterial and venous samples for active
renin, ACE and angiotensin II were again simultaneously
collected at the same time intervals as previously.
Finally, in two adjunctive groups of essential hypertensive
patients (n 5 4 each), the effect of sodium nitroprusside (10,
20 and 30 mg/min 3 5 min each) or acetylcholine (15, 45
and 150 mg/min 3 5 min each) was also evaluated. Patients
were allocated to the different treatment groups in a sequen-
tial order.
Analytical procedures. Active renin (pg/ml) was measured
by radioimmunometric assay using a kit from IRMA Pas-
teur (ERIA Diagnostic, Pasteur, Marnes La Coquette,
France) (15). In our laboratory the intra-assay and interassay
variation coefficient is 9.69% (n 5 20) and 14.5% (n 5 6),
respectively.
Angiotensin II (pg/ml) was determined by radioimmu-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CBF 5 coronary blood flow
LAD 5 left anterior descending coronary artery
RAS 5 renin–angiotensin system
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noassay after extraction of the peptide from plasma by
Sep-Pak C18. This procedure was previously described (6)
and validated by measurement with high performance liquid
chromatography of purified angiotensin II (8). In our
laboratory, the plasma level of purified angiotensin II in
healthy subjects is 13.4 6 7.9 pg/ml (range, 3.3 to 34.8
pg/ml). Serum ACE activity (nmol/min/ml) was measured
by a radioenzymatic method (16) and hematocrit by a
micromethod. Samples from each patient were measured in
the same assay for active renin and angiotensin II, respec-
tively.
Quantitative coronary angiography. Quantitative coro-
nary angiography was performed to convert flow velocity to
an estimate of coronary blood flow (CBF). The proximal
LAD was filmed in right anterior oblique projection inject-
ing 6 to 12 ml of nonionic contrast medium at a rate of 5 to
10 ml/s. Quantitative angiographic analysis was performed
with a MIPRON medical image processing unit (Kontron
Instruments, Munich, Germany) to obtain the cross-
sectional area of the arterial segment 2 to 4 mm distal to the
Doppler tip. The tip of the guiding catheter filmed in the
same projection at the center of the screen, free from
contrast medium and before Doppler probe insertion, was
used as calibration. An estimate of CBF was obtained by
multiplying the mean coronary flow velocity, as measured
directly by the Doppler catheter, by the vessel cross-
sectional area.
Data analysis. Net balance of active renin (pg/min) and
angiotensin II (pg/min) was obtained as the product of the
venous–arterial plasma concentration gradient and coronary
plasma flow (CBF 3 1-hematocrit) (17). Raw data were
analyzed by analysis of variance for repeated measures, and
Scheffe´ test was applied for multiple comparison testing.
Correlation coefficients were calculated using Pearson test.
Results are expressed as mean 6 SEM and 95% confidence
interval.
Drugs. Adenosine (Sigma, Milan, Italy), sodium nitro-
prusside (Malesci, Milan, Italy), acetylcholine HCl (Farmi-
gea S.p.A., Pisa, Italy) and benazeprilat (Novartis, Origgio
[VA], Italy) were obtained from commercially available
sources. Adenosine, acetylcholine and benazeprilat were
diluted in saline to the desired concentrations; sodium
nitroprusside, diluted in glucosate solution, was protected
from light by aluminum foil.
RESULTS
Baseline demographic, hemodynamic and humoral charac-
teristics for normotensive subjects and essential hypertensive
patients are summarized in Table 1. The two groups were
closely matched for age, body mass index, heart rate, urinary
sodium excretion, plasma cholesterol and glucose. Normo-
tensive subjects showed circulating values of active renin and
angiotensin II significantly lower as compared with those of
hypertensive patients. At the time of the study all patients
had reached a constant sodium excretion rate (Table 1).
Adenosine-mediated vascular RAS activation. In nor-
motensive control subjects the infusion of adenosine caused
a dose-dependent increment in CBF, plateauing at the last
dose (from 24.7 6 2.6 [21.5 to 28] to 25 6 3.2 [19.9 to
28.1], 53.1 6 19.1* [29.2 to 76.8], 94.3 6 24.1* [64.3 to
124.3] and 104.3 6 13.1* [88.1 to 120.7] ml/min; *p ,
0.001 vs. basal). During adenosine administration blood
pressure and heart rate did not change significantly (Table
Table 1. Characteristics of Normotensive Subjects and Essential Hypertensive Patients
Parameters
Normotensive Subjects
(n 5 6)
Hypertensive Patients
(n 5 20)
Age (yr) 45.9 6 6.3 (41.7 to 48.3) 47.8 6 5.2 (45.4 to 50.2)
Gender (male/female) 4/2 15/5
Body mass index (kg/m2) 22.7 6 1.3 (21.4 to 24.1) 23.1 6 1.9 (22.2 to 24.1)
Systolic blood pressure (mm Hg) 123.9 6 4.6 (117.7 to 130.3) 158.9 6 8.2 (154.9 to 162.9)
Diastolic blood pressure (mm Hg) 81.3 6 2.5 (78.5 to 83.9) 102.8 6 3.7 (101.1 to 104.6)
Heart rate (beat/min) 61.5 6 4.7 (56.4 to 66.9) 63.9 6 4.1 (62.1 to 65.9)
Active renin (pg/ml) 5.9 6 1.1* (4.4 to 7.2) 10.5 6 2.2 (9.5 to 11.6)
Angiotensin II (pg/ml) 8.2 6 2.9* (4.6 to 11.9) 14.4 6 2.4 (13.1 to 15.4)
Urinary Na excretion (mEq/24 h) 75.3 6 9.8 (63.5 to 87.3) 78.5 6 8.6 (74.3 to 82.4)
Plasma total cholesterol
(mmol/liter)
4.56 6 0.5 (3.98 to 5.13) 4.62 6 0.4 (4.38 to 4.73)
Plasma HDL cholesterol
(mmol/liter)
1.24 6 0.3 (0.96 to 1.65) 1.16 6 0.1 (1.03 to 1.18)
Plasma LDL cholesterol
(mmol/liter)
2.64 6 0.3 (2.28 to 2.91) 2.81 6 0.3 (2.63 to 2.90)
Plasma glucose (mmol/liter) 4.82 6 0.2 (4.6 to 5.1) 4.91 6 0.3 (4.77 to 5.05)
*p , 0.05 or less vs. essential hypertensive patients. Data are reported as mean 6 SEM with 95% confidence interval in
parentheses.
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; Na 5 sodium.
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2). Throughout the experiment, adenosine infusion did not
affect either arterial or venous values of active renin (artery:
from 6.1 6 1.0 [4.7 to 7.3] to 5.8 6 1.2 [4.7 to 7.4], 5.9 6
0.8 [4.9 to 6.9], 5.5 6 0.8 [4.4 to 6.6] and 6.08 6 0.6 [5.3
to 6.9] pg/ml; p 5 NS; vein: from 5.9 6 1.1 [4.6 to 7.4] to
6.0 6 0.9 [4.7 to 7.7], 5.6 6 0.9 [4.4 to 6.8], 5.7 6 1.0 [4.4
to 7.1] and 6.0 6 0.4 [5.4 to 6.6] pg/ml; p 5 NS). When
data were expressed as net balance, it was confirmed that
adenosine failed to cause local active renin release (from
22.7 6 2.7 [24.1 to 20.7] to 5.28 6 5.2 [25.6 to 215.8],
216.9 6 6.4 [242.1 to 28.6], 222.6 6 6.8 [277.5 to 44.6]
and 220.8 6 8.9 [266.3 to 45.6] pg/min). During aden-
osine infusion, arterial and venous values of angiotensin II
did not significantly change (artery: from 10.9 6 2.1 [7.5 to
13.6] to 10.1 6 1.8 [7.9 to 12.4], 11.3 6 2.9 [7.7 to 15.2],
10.8 6 2.3 [7.9 to 13.7] and 10.3 6 3.5 [5.9 to 14.7] pg/ml;
vein: from 11.0 6 2.5 [6.7 to 15.5] to 10.1 6 3.1 [6.2 to
13.9], 11.2 6 2.9 [7.6 to 14.8], 10.3 6 2.2 [7.5 to 13.1] and
9.8 6 3.0 [6.0 to 13.6] pg/ml). Similar to active renin,
angiotensin II net balance was unaffected by adenosine
(from 24.8 6 3.7 [29.3 to 20.5] to 22.4 6 3.2 [26.3 to
1.2], 28.4 6 4.4 [217.3 to 22.9] and 222.6 6 7.8 [254.2
to 29.8] pg/min).
In essential hypertensive patients the infusion of adeno-
sine caused a dose-dependent increment in CBF which was
similar to that observed in normotensive control subjects
(from 22.0 6 4.5 [18.5 to 25.9] to 28.9 6 6.1 [21.5 to
/37.9], 50.8 6 15.5* [35.4 to 69.5], 107.4 6 20.2* [85.4 to
121.4] and 115.1 6 19.8* [91.2 to 127.6] ml/min; *p ,
0.001 vs. basal). During adenosine administration blood
pressure and heart rate did not change significantly (Table
2). Intracoronary adenosine infusion did not affect arterial
values of active renin. In contrast, intracoronary adenosine
significantly (p , 0.05) increased venous active renin at 1
and 10 mg/min; its effect started to decline at 100 mg/min
and was exhausted at 1,000 mg/min (Fig. 1). Data expressed
as net balance indicate that adenosine caused a dose-
dependent release of active renin at the first two doses (from
20.65 6 1.3 [22.5 to 1.4] to 64.7 6 9.3* [42.5 to 83.5] and
146.9 6 23.8* [108.4 to 199.2] pg/min; *p , 0.001 vs.
basal) which decreased at the greater infusion rates (86.1 6
18.8* [51.5 to 117.4] and 2.3 6 3.2 [22.6 to 4.9] pg/min;
p , 0.001 vs. basal) (Fig. 2), suggesting that over three
4-min periods, approximately 1.90 pg of active renin was
worked out from the myocardium by the effects of adeno-
sine.
Adenosine administration did not modify arterial values
of angiotensin II, whereas it dose-dependently increased
venous angiotensin II at the first three doses. At the fourth
dose, venous angiotensin II declined but was still signifi-
cantly greater as compared with baseline and with the
corresponding arterial values (Fig. 1). Thus, in terms of net
balance, adenosine caused a dose-dependent release of
angiotensin II at the 1, 10 and 100 mg/min infusion rates,
Table 2. Hemodynamic Effects of Intracoronary Adenosine Infusion in Normotensive Subjects and Essential Hypertensive Patients
Baseline
Adenosine
1 mg/ml 10 mg/ml 100 mg/ml 1,000 mg/ml
Normotensive subjects
Systolic aortic pressure (mm Hg) 122 6 11 124 6 10 127 6 12 126 6 12 124 6 11
Diastolic aortic pressure (mm Hg) 78 6 2 79 6 2 78 6 3 79 6 2 79 6 2
Mean aortic pressure (mm Hg) 92.6 6 11 94 6 10 94.3 6 11 94.6 6 12 94 6 10
Heart rate (beats/min) 80 6 7 77 6 6 78 6 7 81 6 8 82 6 7
Hypertensive patients
Systolic aortic pressure (mm Hg) 162 6 10 164 6 13 167 6 12 166 6 10 164 6 13
Diastolic aortic pressure (mm Hg) 90 6 2 91 6 2 91 6 3 90 6 2 91 6 2
Mean aortic pressure (mm Hg) 114 6 11 115.3 6 10 116.3 6 11 115.3 6 12 115.3 6 10
Heart rate (beats/min) 78 6 9 78 6 7 81 6 8 78 6 9 80 6 9
Figure 1. Line graphs show arterial (open circles) and venous
(solid circles) concentrations of active renin (A.R.) and angioten-
sin II (Ang II) during intracoronary adenosine infusion in 12
essential hypertensive patients. Data are shown as mean 6 SEM.
*p , 0.05 or less.
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which decreased at 1,000 mg/min (from 27.8 6 2.1 [216.4
to 13.2] to 50.8 6 4.7* [36.4 to 71.9], 139.7 6 24.7* [97.4
to 172.6] 616 6 47.9* [312.5 to 944.8] and 198.1 6 27.5*
[101.6 to 291.4] pg/min; *p , 0.001 vs. basal) (Fig. 2).
Active renin and angiotensin II release induced by exoge-
nous adenosine infusion in coronary vessels (calculated as
the area under the curve of venous–arterial differences)
showed a positive correlation (r 5 0.73; p , 0.01). More-
over, when maximal individual increments of active renin
and angiotensin II induced by adenosine were tested versus
the basal circulating renin profile, we found a significant
correlation between local vascular active renin (r 5 0.78;
p , 0.001), angiotensin II (r 5 0.71; p , 0.001) release and
circulating active renin.
Effect of ACE inhibition on adenosine-mediated vascu-
lar RAS activation. As in the previous experiment, in this
subgroup (n 5 5) of essential hypertensive patients adeno-
sine also caused a similar dose-dependent increment in
CBF, plateauing at the last dose (from 21.4 6 4.5 [15.7 to
27.1] to 30.2 6 7 [21.4 to 38.9], 53.3 6 19.3* [29.3 to
77.3], 105.1 6 12.1* [89.9 to 120.2] and 111.7 6 8.0*
[101.7 to 121.6] ml/min; *p , 0.001 vs. basal), without
affecting blood pressure and heart rate (data not shown).
Likewise, adenosine infusion did not modify arterial levels
of active renin, whereas it increased venous values at the first
two doses, an effect that declined at 100 and 1,000 mg/min
(Fig. 3A, left). Thus, similarly to the previous experiment,
the net balance showed that adenosine induced a dose-
dependent release of active renin at the first two doses,
which decreased during the higher infusion rates (from
215.9 6 2.1 [230.6 to 16.9] to 44.4 6 5.9* [27.4 to 68.6],
196 6 32.7* [127.3 to 251.4], 60.9 6 18.9* [21.5 to 99.3]
and 7.8 6 3.5 [1.5 to 14.4] pg/min; *p , 0.001 vs. basal).
Arterial angiotensin II values did not change under adeno-
sine infusion, whereas venous angiotensin II significantly
increased at the first three doses and declined at the highest
rates (Fig. 3B, left). Again, in terms of net balance,
adenosine caused a dose-dependent release of angiotensin II
at the 1-, 10-, and 100-mg/min infusion rates, which
decreased at 1,000 mg/min (from 27.7 6 2.5 [215.3 to 3.9]
to 79.4 6 6.3* [34.5 to 131.6], 150.3 6 29.7* [91.4 to
201.6], 630 6 54.1* [374.5 to 922.3] and 127.1 6 19.5*
[83.7 to 189.3] pg/min; *p , 0.001 vs. basal).
When benazeprilat was infused, arterial ACE activity did
not change (from 88.6 6 4.1 to 89.4 6 3.8 nmol/ml/min;
p 5 NS), whereas venous ACE activity was suppressed
(from 89.3 6 3.4 to 13.7 6 2.8 nmol/ml/min; p , 0.05 vs.
basal). Benazeprilat infusion did not significantly modify
either basal CBF (from 18.0 6 3.0 [14.2 to 21.8] to 17.6 6
2.3 [14.7 to 20.5] ml/min; p 5 NS) or the increment in
CBF induced by adenosine (from 17.6 6 2.3 to 26.9 6 5.2
[20.3 to 33.4], 60.2 6 15.7 [40.7 to 79.7], 98.0 6 19.8 [73.4
to 122.6] and 116.8 6 14.5 [98.7 to 134.8] ml/min).
Figure 2. Bars show net balance of active renin (A.R.) and
angiotensin II (Ang II) in 12 essential hypertensive patients. Data
are shown as mean 6 SEM. *p , 0.05 or less versus basal.
Figure 3. (A) Line graphs show arterial (open circles) and venous
(solid circles) concentrations of active renin (A.R.) in basal
conditions (left) and in the presence of benazeprilat infusion
(BEN, 25 mg/min, right) in five essential hypertensive patients.
Data are shown as mean 6 SEM. *p , 0.05 or less. (B) Line
graphs show arterial (open circles) and venous (solid circles)
concentrations of angiotensin II (Ang II) in basal conditions (left)
and in the presence of benazeprilat infusion (right) in five essential
hypertensive patients. Data are shown as mean 6 SEM. *p , 0.05
or less.
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Arterial active renin values were unaffected, either when
benazeprilat was infused alone or when it was coinfused
with adenosine. In contrast, venous active renin values were
increased by benazeprilat infusion, without further modifi-
cation during adenosine coinfusion (Fig. 3A, right). Finally,
benazeprilat significantly (p , 0.005) reduced basal angio-
tensin II venous values and abolished the adenosine-
mediated venous angiotensin II increments, without chang-
ing arterial concentrations (Fig. 3B, right).
Effect of sodium nitroprusside and acetylcholine on
vascular RAS activation. In four adjunctive essential hy-
pertensive patients the infusion of sodium nitroprusside
caused a dose-dependent increment in CBF comparable to
that induced by adenosine (from 25.4 6 9.1 [16.5 to 31.4]
to 42.5 6 11* [31.5 to 55.7], 72.5 6 17.4* [49.5 to 87.2]
and 103.8 6 24.2* [92.5 to 112.6] ml/min; *p , 0.001 vs.
basal) without affecting either arterial or venous values of
active renin (artery: from 9.5 6 2.3 [6.4 to 13.2] to 10.2 6
1.8 [6.9 to 14.1], 9.7 6 2.4 [7.1 to 12.9] and 9.8 6 2.1 [7.5
to 13.3] pg/ml; p 5 NS; vein: from 9.5 6 2.2 [7.5 to 13.1]
to 10.2 6 1.8 [8.2 to 13.5], 9.7 6 2.4 [6.8 to 12.8] and
9.3 6 2.4 [6.5 to 13.1] pg/ml; p 5 NS) or angiotensin II
(artery: from 13.1 6 1.8 [10.1 to 15.1] to 13.5 6 2.8 [9.8 to
15.7], 12.6 6 3.0 [9.8 to 14.2] and 13.1 6 4.2 [10.5 to 17.9]
pg/ml, p 5 NS; vein: from 13.5 6 1.3 [9.5 to 15.8] to
13.3 6 2.3 [10.5 to 15.9], 13.2 6 2.3 [9.8 to 15.7] and
13.2 6 1.6 [10.1 to 15.4] pg/ml, p 5 NS). Similarly, in one
adjunctive subgroup (n 5 4) of essential hypertensive
patients the infusion of acetylcholine induced a dose-
dependent increment in CBF comparable to that induced by
adenosine (from 18.3 6 2.4 [18.3 to 25.4] to 37.3 6 9.7*
[21.5 to 49.8], 64.6 6 13.7* [50.1 to 75.9] and 108.1 6
23.5* [93.5 to 117.2] ml/min; *p , 0.001 vs. basal).
Throughout the experiment, acetylcholine administration
did not affect either arterial or venous values of active renin
(artery: from 11.1 6 1.2 [9.1 to 12.7] to 10.9 6 0.5 [9.5 to
12.9], 10.5 6 1.3 [9.1 to 13.1] and 11.3 6 1.6 [9.5 to 12.8]
pg/ml; p 5 NS; vein: from 12.5 6 2.9 [10.1 to 14.5] to
13.4 6 3.0 [11.4 to 15.8], 12.5 6 3.3 [10.4 to 15.2] and
13.0 6 2.9 [10.7 to 16.1] pg/ml; p 5 NS) or angiotensin II
(artery: from 13.2 6 1.3 [11.4 to 15.1] to 13.0 6 1.2 [11.5
to 14.9], 13.4 6 1.3 [10.9 to 14.8] and 13.1 6 1.5 [10.9 to
15.9] pg/ml; p 5 NS; vein: from 13.9 6 1.2 [11.5 to 16.5]
to 14.9 6 2.8 [12.5 to 17.1], 13.9 6 3.6 [11.3 to 16.2] and
14.2 6 2.9 [12.5 to 17.1] pg/ml; p 5 NS). Aortic blood
pressure and heart rate were not modified by sodium
nitroprusside and acetylcholine infusion (data not shown).
DISCUSSION
The present data indicate that in patients with essential
hypertension, but not in normotensive subjects, intracoro-
nary infusion of adenosine causes an increase in active renin
and angiotensin II in the coronary circulation, an effect
which is blocked by intracoronary administration of the
ACE inhibitor benazeprilat. These results suggest that
adenosine could activate angiotensin II production in the
coronary circulation of patients with essential hypertension.
This finding is in line with previous observations obtained
in the forearm vasculature of essential hypertensive patients
(12) indicating that intrabrachial adenosine caused local
release of angiotensin II, an effect blunted by either theoph-
ylline, an adenosine receptor antagonist, or the ACE inhib-
itor captopril.
Adenosine-induced vascular RAS activation. In the cor-
onary circulation the effect of adenosine on the release of
active renin and angiotensin II seems to be specific, since
two chemically unrelated vasodilators such as sodium nitro-
prusside, acting directly on smooth muscle cells, or acetyl-
choline, a muscarinic agonist, did not modify coronary
active renin and angiotensin II net balance despite a
vasodilation comparable to that induced by adenosine.
Moreover, activation of systemic RAS induced by our
experimental intervention can be reasonably excluded by the
lack of modifications in blood pressure, heart rate and
arterial active renin and angiotensin II. It is therefore
conceivable that the increase in active renin and angiotensin
II observed in the coronary LAD during adenosine infusion
could be determined by a direct effect of the purine
compound on the vessel wall. This possibility is reinforced
by the series with benazeprilat. Thus, the ACE inhibitor,
when directly infused into the LAD, caused local but not
systemic blockade of both basal and adenosine-mediated
production of angiotensin II, further suggesting that the
peptide is synthesized inside the coronary circulation.
Adenosine-stimulated active renin release depends upon
the subtype of adenosine receptor involved, since stimula-
tion of A1- or A2-adenosine receptors leads to inhibition
and increase of renin release, respectively (11,18). In agree-
ment with this possibility, the vasodilator response induced
in anesthetized rats by selective activation of A2-adenosine
receptors was potentiated by losartan, an angiotensin II
receptor antagonist, suggesting that A2-mediated RAS
stimulation participates in vascular control (19).
Concerning the mechanism through which adenosine
could activate the RAS, available evidence indicates that
compounds that increase cyclic adenosine monophosphate,
such as adenosine or beta-adrenoceptor agonists, can stim-
ulate the release of active renin in various experimental
models (20). However, this mechanism seems to operate
exclusively on renally derived renin (20).
Relationship between circulating and vascular RAS. Al-
though a recent review of experimental evidence raised some
doubts concerning the local synthesis of renin in heart and
extrarenal blood vessels, favoring a renal origin of the tissue
enzyme (21), at the present time this question is still
debated (22–24). It has however been demonstrated in the
heart of intact pigs that vascular active renin is taken up
from the circulation into the tissue interstitium (25) and in
the forearm of essential hypertensive patients that release of
vascular active renin is strictly correlated to the profile of
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circulating plasma renin activity (8). In the present study,
the maximal individual local active renin and angiotensin II
release showed a significant positive correlation with the
circulating renin profile. Thus it can be speculated that even
in the coronary vessels of patients with essential hyperten-
sion, vascular active renin is taken up from circulating blood.
In line with this possibility is the finding that adenosine
does not activate the RAS in normotensive subjects, who
show a lower circulating RAS profile as compared with
essential hypertensive patients. Nevertheless, whether lo-
cally synthesized renin also contributes to adenosine-
mediated angiotensin II production cannot be ascertained
by the present experimental design.
In the present report active renin was evaluated by
radioimmunoassay (15). This is at variance with the com-
mon knowledge that the most popular method for assessing
RAS activity is the enzymatic assay, based on the quantifi-
cation of angiotensin I generated by the reaction between
renin and its substrate (26). However, this classical method,
although very convenient for estimating the action of the
renin system, has several methodologic difficulties. The
recently developed immunometric assay of renin potentially
overcomes the limitations of the enzymatic assay because
the use of monoclonal antibodies allows the direct quanti-
fication of the active form of the enzyme. This possibility is
substantiated by the demonstration of a greater reproduc-
ibility of the immunometric as compared with the enzy-
matic assay. Finally, a very high correlation exists between
the two methods in different experimental conditions (8,15).
Whatever the origin of vascular active renin, the present
observation that adenosine increases active renin and angio-
tensin II concentrations only in the coronary circulation,
without changing arterial values, indicates that even if
vascular renin is taken up from plasma, it can be activated to
produce angiotensin II independently of the circulating
RAS. This in turn suggests that the cardiac renin–
angiotensin pathway can be considered a local vascular
system, at least from a functional point of view.
Behavior of coronary blood flow and vascular RAS. A
discrepancy exists between the behavior of CBF, active
renin and angiotensin II during adenosine infusion.
Whereas CBF increases in a dose-dependent manner to
reach a plateau at the last infusion rate of adenosine, the
release increments of both active renin and angiotensin II
are transient. This finding seems to indicate that despite a
maximal stimulation of adenosine receptors, activation of
the local RAS is a short-lasting event that rapidly declines.
Such an observation is in agreement with previous data from
our laboratory (8), which indicate that a prolonged (60 min)
infusion of isoproterenol, despite causing a stable increase in
forearm blood flow, leads to a rapid but short-lasting release
of plasma renin activity and angiotensin II in the forearm of
patients with essential hypertension. The present data
therefore seem to reinforce the hypothesis that renin is
stored in vessel walls as a pool that can be easily activated to
produce angiotensin II, but is then immediately exhausted.
Finally the delay in production of angiotensin II as com-
pared with active renin is likely due to a time lag in
increasing local concentrations of angiotensinogen or ACE.
Conclusions. In conclusion, the present data indicate that
exogenous adenosine causes the release of active renin and
angiotensin II from the coronary vessels of patients with
essential hypertension. This finding may have potential
clinical relevance, considering the beneficial effect of ACE
inhibitors in experimental myocardial ischemia (27–29) and
in patients with acute myocardial infarction (30–36). It is
tempting to speculate that adenosine produced by hypoxic
tissue during myocardial ischemia can reach coronary blood
(37) and activate angiotensin II production. Moreover,
vascular angiotensin II could also be important in the
pathogenesis of cardiac remodeling, a pathologic condition
that can be reversed by ACE inhibitors (38–42). However,
further investigations are needed to demonstrate this hy-
pothesis.
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